Caroline Hopkins Legaspi

The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with the greatest potential. 

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon established CAR T-cell therapies.

The iMMagine-1 data suggest anito-cel could have a differentiated safety and efficacy profile compared to available BCMA-directed therapies. 

The data suggest that multiple myeloma patients on Janssen's CAR T-cell therapy lived longer than on BMS's but experienced more severe side effects. 

Lymphoma patients better tolerated the CAR T-cell therapy manufactured on-site at the Sheba Medical Center than they did the commercially available options. 

The non-cryopreserved CD19- and CD20-directed CAR T-cell therapy zamto-cel is manufactured in a closed-system device that could enable point-of-care treatment. 

The firm presented early data for a blood-based approach to screen prostate cancer patients for PSMA, which it believes has advantages over PET imaging. 

The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell therapy to date. 

As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role for biomarkers to guide their use. 

A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.